Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Saturday, June 12, 2010

press release:- Correlogic Systems Obtains CE Mark for OvaCheck®



Correlogic Systems Obtains CE Mark for OvaCheck® PDF Print E-mail
Saturday, 12 June 2010
"Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians...."

ASCO abstract: Association of Lynch syndrome and risk of invasive cervical cancer.



Abstract:
Background: Lynch syndrome, a hereditary cancer syndrome characterized by germline mutations in mismatch repair (MMR) genes, is associated with an elevated lifetime risk of cancer development, predominantly endometrial, colorectal and ovarian. To date, no increased risk of cervical cancer for mutation carriers has been reported

Hematuria - Urology at UCLA




We are a new and the first Scottish Charity dedicated to Ovarian Cancer




Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis



CONCLUSIONS: OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use. There is no evidence that recent OC formulations increase breast cancer risk in carriers

Menopausal hormone therapy and risk of colorectal cancer in the European prospective investigation into cancer and nutrition



"Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk."

Giving Honest Information to Patients With Advanced Cancer Maintains Hope - Cancer Network




F.D.A. Faults 5 Companies on Genetic Tests - NYTimes.com




Avastin, Cancer Drug, Can Cause Kidney Damage - ABC News + patient response/ovarian cancer (proteinuria)



"........The manifestation of proteinuria, even significant proteinuria with therapy, was seen in those pilot studies," said Dr. Bryan Becker, president of the National Kidney Foundation, who is not affiliated with the group that carried out the current study.

However, some doctors said the incidence of proteinuria with the treatment is not a cause for alarm.

"The 2 to 3 percent that have proteinuria is minor," said Dr. Otis Brawley, the American Cancer Society's chief medical and scientific officer, who likewise had no involvement with this research.

It also doesn't concern 46-year-old Julie Del Giorno, a Pennsylvania woman who took Avastin to treat her ovarian cancer as part of a clinical trial last year.

Luckily, she now has no signs of cancer left.

"I'm doing really well. Everything's been fine -- my CT scans have been normal," she said.

After reading about the side effects of Avastin and consulting with her doctor, she decided to give it a try.

"There are always risks involved, and I had trust in the doctors I was working with that it was a good option," she said"....cont'd

Cancer Caregivers Share Patient Stresses